)
Celldex Therapeutics (CLDX) investor relations material
Celldex Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key milestones and clinical development
Initiated two phase 3 studies in cold urticaria and symptomatic dermographism in December 2025, each with 120 patients, targeting 18-month timelines.
Ongoing two large phase 3 CSU studies across 500+ centers in 43 countries, aiming for 1,830 patients and enrollment completion by summer 2026.
Phase 2 studies in prurigo nodularis and atopic dermatitis completed; data readouts expected in the second half of 2026, with phase 3 studies to follow based on results.
Exploring additional indications such as food allergy, allergic rhinitis, and chronic pruritic itch, with potential development starting late 2026 or 2027.
Bispecific antibody CDX-622 in healthy volunteer studies, with multiple ascending dose and subcutaneous data expected in summer; proof-of-mechanism asthma study initiated.
Clinical data and physician feedback
Phase 2 CSU data show rapid and high complete response rates (up to 70%) and durable effects, with 41% maintaining response seven months post-treatment.
Quality of life and angioedema improvements reported, generating strong enthusiasm among investigators.
Long-term durability data presented at major conferences, with ongoing discussions about changing treatment paradigms.
Retreatment in CIndU study demonstrated successful efficacy upon symptom recurrence.
Safety and study design
Safety profile remains consistent and well-tolerated, with mild, reversible side effects related to KIT inhibition.
Phase 3 CSU studies closely mirror phase 2 design, with the addition of a loading dose; primary endpoint at 12 weeks, but full analysis after 24 weeks.
Large safety database being built with over 1,800 patients in CSU studies, supporting regulatory requirements.
Next Celldex Therapeutics earnings date
Next Celldex Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)